报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2025年4月，据medical design and outsourcing网站报道，捷迈邦美Zimmer Biomet披露了其首席执行官、其他高管以及普通员工的薪酬变动，预计均有 所上涨。与此同时，GE医疗公布其高管以及普通员工的薪酬均有所下降。 2024年Zimmer Biomet 薪酬最高的高管是总裁兼首席执行官 Ivan Tornos，年薪为 1500万美元 ，其中包括120万美元的薪水、1180万美元的股票奖励和170万美 元的奖金。Ivan Tornos还获得了价值26万美元各类补贴，总薪酬比前一年的1020万美元 上 涨47%。 Suketu Upadhyay：首席财务官兼财务、运营以及供应链执行副总裁 # 捷迈邦美高管 薪酬 排名 Ivan Tornos：总裁兼首席执行官 年薪为 5 90万美元 ，其中包括87.6万美元的薪水、400万美元的股票奖励和82.09万美元的奖金等，此外获得价值18万美元左右的各类补贴，总薪酬较上 一年的1040万美元 下降43%。 Wilfre ...

报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2025年4月，据medical design and outsourcing网站报道，捷迈邦美Zimmer Biomet披露了其首席执行官、其他高管以及普通员工的薪酬变动，预计均有 所上涨。与此同时，GE医疗公布其高管以及普通员工的薪酬均有所下降。 2024年Zimmer Biomet 薪酬最高的高管是总裁兼首席执行官 Ivan Tornos，年薪为 1500万美元 ，其中包括120万美元的薪水、1180万美元的股票奖励和170万美 元的奖金。Ivan Tornos还获得了价值26万美元各类补贴，总薪酬比前一年的1020万美元 上 涨47%。 Suketu Upadhyay：首席财务官兼财务、运营以及供应链执行副总裁 # 捷迈邦美高管 薪酬 排名 Ivan Tornos：总裁兼首席执行官 年薪为 5 90万美元 ，其中包括87.6万美元的薪水、400万美元的股票奖励和82.09万美元的奖金等，此外获得价值18万美元左右的各类补贴，总薪酬较上 一年的1040万美元 下降43%。 Wilfre ...

GE HealthCare Technologies (GEHC) shares soared 10.6% in the last trading session to close at $64.98. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 31.4% loss over the past four weeks.The upside can be attributed to relief-rally across global markets following the announcement of a 90-day pause on tariff hike by the United States.This medical technology company is expected to post quarterly earnings of $0.91 per share in its up ...

If you like to see more ideas, please subscribe to the premium service "Value in Corporate Events" here and try the free trial. In this service we cover major earnings events, M&A, IPOs and other significant corporate events with actionable ideas. Furthermore, we provide coverage of situations and names on request!Shares of GE HealthCare (NASDAQ: GEHC ) have been a publicly traded entity since early 2023, when the healthcare business was spun off from GE. A $60 stock at the time, has largely traded in a $60 ...

报名：首届全球眼科大会 | 议程更新 报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 合作伙伴征集：2025全球手术机器人大会 过去一周，多家知名医疗科技公司的股票表现不佳，公司 正在努力应对特朗普政府发起的新一轮全球贸易 战。 标准普尔500指数（S&P 500）昨日短暂进入熊市，随着关于政府和其他国家可能采取的关税措施的 混乱消息，该指数大幅波动。 总体而言，标准普尔500指数在过去一个月下跌了 12% ，在过去五天内下跌了 9% 。 医疗科技股在3月就因特朗普的关税政策而下跌。特朗普上周对几乎所有国家的进口商品实施新的税收， 引发了此轮暴跌。以下是过去一个月（百分比为四舍五入）10大医疗科技公司的股票表现： | | 10大医疗科技公司股票表现 | | | --- | --- | --- | | 序号 | Company | Stock Performance (1 Month) | | 1 | Medtronic (NYSE: MDT) | -12% | | 2 | Johnson & Johnson (NYSE: JNJ) | -10% | | 3 | Stryker ( ...

Shares in GE HealthCare Technologies (GEHC -10.04%) were down 9.5% at 1 p.m. today. The decline follows the U.S.'s wide-scale implementation of tariffs. GE HealthCare is a truly global company, and the tariff actions will negatively impact its business.GE HealthCare and tariffsThe company generated about $9 billion in revenue from North America in 2024, and $10.7 billion from the rest of the world (including $2.4 billion from China). It's a global company, competing with leading healthcare equipment compani ...

GE HealthCare Technologies Inc. (GEHC) , yesterday, announced the completion of its acquisition of the remaining 50% stake in Nihon Medi-Physics Co., Ltd ("NMP") from Sumitomo Chemical, giving it full ownership. The intent to acquire the remaining 50% stake in NMP was announced in December 2024. GE HealthCare acquired Amersham plc in 2004 and subsequently held a 50% stake in NMP. As part of GE HealthCare, NMP is expected to play a key role in bringing its deep expertise and scale to global innovators lookin ...

GE HealthCare Technologies Inc. (GEHC) recently unveiled Revolution Vibe, an advanced computed tomography (CT) system featuring Unlimited One-Beat Cardiac imaging designed to produce high-quality, consistent images even in complex cases such as atrial fibrillation. Integrated with cutting-edge technologies, Revolution Vibe enhances diagnostic speed and accuracy while improving patient comfort and optimizing workflow efficiency. As medical institutions continue to seek advanced imaging solutions that balance ...

GEHC further stated that the FDA approved Flyrcado for patients with known or suspected CAD in 2024. This is expected to deliver higher diagnostic efficacy, unlike SPECT MPI, the predominant procedure used in nuclear cardiology at present. GE HealthCare's management believes that the launch of Flyrcado represents a significant advancement in cardiac care, providing a new, highly effective diagnostic tool for those with known or suspected CAD. Additionally, Flyrcado has been granted traditional pass-through ...

Company Overview - GE HealthCare Technologies Inc. (GEHC) has launched the Invenia Automated Breast Ultrasound (ABUS) Premium, a 3D ultrasound product featuring advanced AI capabilities aimed at improving screening for patients with dense breasts [1][2] - The Invenia ABUS Premium has received FDA premarket approval and is set to be launched in key markets by 2025 [1] Product Significance - Approximately 71% of breast cancers occur in dense breast tissue, with studies indicating that 40% of women and 70% of Asian women have dense breasts, increasing their cancer diagnosis risk [5] - The Invenia ABUS Premium's AI features enhance clinical workflow by reducing scanning time and improving detection of small, early-stage cancers [6][7] Market Potential - The global breast cancer diagnostics market was valued at $4.3 billion in 2022 and is projected to grow at a CAGR of 7.4% from 2023 to 2030, driven by technological advancements and rising breast cancer prevalence [8] Financial Performance - GE HealthCare has a market capitalization of $37.27 billion and an earnings yield of 5.8%, significantly higher than the industry average of 0.3% [4] - The company reported an earnings surprise of 15.1% in the last quarter [4] Stock Performance - Following the product announcement, GEHC shares declined by nearly 1.1%, despite historical trends showing that product innovations typically boost top-line growth [3] - Over the past year, GEHC shares have decreased by 6.6%, contrasting with a 9.9% rise in the industry and a 9.1% gain in the S&P 500 [10]